Publication & Citation Trends
Publications
0 total
TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade
Cited by 2
Semantic Scholar
BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia
Cited by 1
Semantic Scholar
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome OA
Cited by 15
Semantic Scholar
MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
Cited by 6
Semantic Scholar
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia OA
Cited by 31
Semantic Scholar
Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study OA
Cited by 47
Semantic Scholar
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. OA
Cited by 272
Semantic Scholar
Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage OA
Cited by 49
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(35)
Protein Degradation and Inhibitors
(20)
Chronic Myeloid Leukemia Treatments
(19)
CAR-T cell therapy research
(18)
Cutaneous lymphoproliferative disorders research
(18)
Affiliations
National Institutes of Health
The University of Texas MD Anderson Cancer Center
Harvard University
Gustavus Adolphus College
University of California, San Francisco